MedPacto Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Public

  • Employees
  • 57

Employees

  • Stock Symbol
  • 235980

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $4.32
  • (As of Tuesday Closing)

MedPacto General Information

Description

MedPacto Inc is a drug discovery and development company based in South Korea. It is engaged in developing anticancer drugs and medicines which focuses on therapeutics targeting cancer and autoimmune diseases. Its products are in pipeline.

Contact Information

Website
www.medpacto.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 92 Myeongdal-ro, Seocho-gu
  • Seoul, Seocho-gu 06668
  • South Korea
+82
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
KRX
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 92 Myeongdal-ro, Seocho-gu
  • Seoul, Seocho-gu 06668
  • South Korea
+82

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

MedPacto Stock Performance

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$4.32 $4.28 $4.23 - $12.82 $144M 33.6M 191K -$0.91

MedPacto Financials Summary

In Thousands,
USD 		TTM 30-Jun-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 125,781 189,967 348,360 908,283
EBITDA (20,239) (25,536) (19,805) (7,168)
Net Income (20,790) (27,018) (27,670) (14,876)
Total Assets 48,325 62,447 85,269 112,053
Total Debt 6,055 1,884 50,183 42,770
Public Fundamental Data provided by Morningstar, Inc. disclaimer

MedPacto Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore MedPacto‘s full profile, request access.

Request a free trial

MedPacto Patents

  • 55

    Total Documents Applications and Grants

  • Total Patents Families

  • 34

    Granted

  • 18

    Pending

  • Expiring in next 12 mo

MedPacto Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-12006315-B2 Intermediate useful for the synthesis of tgf-beta inhibitors and a method of preparing tgf-beta inhibitors using the same Active 25-Mar-2022
US-20230303568-A1 Intermediate useful for the synthesis of tgf-beta inhibitors and a method of preparing tgf-beta inhibitors using the same Active 25-Mar-2022
AU-2022284686-A1 Tm4sf19 inhibitor and uses thereof Pending 03-Jun-2021
CA-3220026-A1 Tm4sf19 inhibitor and uses thereof Pending 03-Jun-2021
EP-4349358-A1 Tm4sf19 inhibitor and uses thereof Pending 03-Jun-2021 A61K38/00
To view MedPacto’s complete patent history, request access »

MedPacto Executive Team (4)

Name Title Board Seat
Seong-Jin Kim Ph.D Chief Executive Officer & Board Member
Seon-Jeong Kim Chief Financial Officer, Senior Managing Director & Head-Management Support
Saerom Kim Chief Licensing & Planning Officer
You’re viewing 3 of 4 executive team members. Get the full list »

MedPacto Board Members (4)

Name Representing Role Since
Seong-Jin Kim Ph.D MedPacto Chief Executive Officer & Board Member
Young-Jung Kwon Self Board Member
Young-Sik Kim Self Board Member
Youn-Sik Song Self Board Member
To view MedPacto’s complete board members history, request access »

MedPacto Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

MedPacto Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Celloram 01-Jan-2020 Drug Discovery
To view MedPacto’s complete investments history, request access »

MedPacto ESG

Risk Overview

Risk Rating

Updated December, 01, 2023

35.33 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 16,009

Rank

Percentile

Pharmaceuticals

Industry

of 909

Rank

Percentile

Pharmaceuticals

Subindustry

of 446

Rank

Percentile

To view MedPacto’s complete esg history, request access »

MedPacto FAQs

  • When was MedPacto founded?

    MedPacto was founded in 2013.

  • Who is the CEO of MedPacto?

    Seong-Jin Kim Ph.D is the CEO of MedPacto.

  • Where is MedPacto headquartered?

    MedPacto is headquartered in Seoul, South Korea.

  • What is the size of MedPacto?

    MedPacto has 57 total employees.

  • What industry is MedPacto in?

    MedPacto’s primary industry is Drug Discovery.

  • Is MedPacto a private or public company?

    MedPacto is a Public company.

  • What is MedPacto’s stock symbol?

    The ticker symbol for MedPacto is 235980.

  • What is the current stock price of MedPacto?

    As of 08-Oct-2024 the stock price of MedPacto is $4.32.

  • What is the current market cap of MedPacto?

    The current market capitalization of MedPacto is $144M.

  • What is MedPacto’s annual earnings per share (EPS)?

    MedPacto’s EPS for 12 months was -$0.91.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »